Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AOWDF NASDAQ:CGBD OTCMKTS:ELMTY OTCMKTS:OROCF OTCMKTS:OXBDF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAOWDFAO World$2.05$2.05$1.99▼$3.27$938.42M-0.17900 shsN/ACGBDCarlyle Secured Lending$14.17+0.4%$13.96$13.12▼$18.74$722.66M0.85266,209 shs160,880 shsELMTYElementis$8.61$7.43$8.61▼$9.20$1.27B0.27111 shs12 shsOROCFAllkem$6.80+1.5%$6.80$5.34▼$11.66N/A1.6814,560 shs1,900 shsOXBDFOxford BioMedica$4.77$4.27$3.15▼$5.68$505.43M1.11600 shs11 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAOWDFAO World0.00%0.00%0.00%0.00%0.00%CGBDCarlyle Secured Lending+1.66%+1.40%0.00%+0.71%-22.08%ELMTYElementis0.00%0.00%+19.55%+19.55%+15.07%OROCFAllkem0.00%0.00%0.00%0.00%0.00%OXBDFOxford BioMedica0.00%+12.77%+2.36%+51.43%+28.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAOWDFAO WorldN/AN/AN/AN/AN/AN/AN/AN/ACGBDCarlyle Secured Lending1.3505 of 5 stars0.83.01.70.02.70.01.9ELMTYElementisN/AN/AN/AN/AN/AN/AN/AN/AOROCFAllkemN/AN/AN/AN/AN/AN/AN/AN/AOXBDFOxford BioMedicaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAOWDFAO World 0.00N/AN/AN/ACGBDCarlyle Secured Lending 1.60Reduce$14.754.46% UpsideELMTYElementis 4.00Strong BuyN/AN/AOROCFAllkem 0.00N/AN/AN/AOXBDFOxford BioMedica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ELMTY, AOWDF, OROCF, OXBDF, and CGBD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025CGBDCarlyle Secured LendingB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/8/2025CGBDCarlyle Secured LendingOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$17.00 ➝ $15.005/8/2025CGBDCarlyle Secured LendingWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $13.004/28/2025CGBDCarlyle Secured LendingWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.004/24/2025CGBDCarlyle Secured LendingJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$17.00 ➝ $14.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAOWDFAO World$2.13B0.44N/AN/A$0.22 per share9.30CGBDCarlyle Secured Lending$232.59M3.09$1.93 per share7.33$16.80 per share0.84ELMTYElementis$738.30M1.72$0.90 per share9.58$5.12 per share1.68OROCFAllkem$1.21BN/A$1.10 per share6.16$8.96 per shareN/AOXBDFOxford BioMedica$111.34M4.54N/AN/A$1.01 per share4.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAOWDFAO World-$41.52MN/A0.00204.54N/AN/AN/AN/AN/ACGBDCarlyle Secured Lending$88.98M$1.3510.468.11N/A32.72%10.49%4.88%8/4/2025 (Estimated)ELMTYElementis-$47.80MN/A0.0015.94N/AN/AN/AN/A7/31/2025 (Estimated)OROCFAllkem$441.71MN/A0.0042.50N/AN/AN/AN/AN/AOXBDFOxford BioMedica-$195.90MN/A0.00N/AN/AN/AN/AN/AN/ALatest ELMTY, AOWDF, OROCF, OXBDF, and CGBD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025CGBDCarlyle Secured Lending$0.39N/AN/AN/A$67.53 millionN/A5/6/2025Q1 2025CGBDCarlyle Secured Lending$0.43$0.41-$0.02$0.25$55.50 million$54.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAOWDFAO WorldN/AN/AN/AN/AN/ACGBDCarlyle Secured Lending$1.6011.33%N/A118.52%N/AELMTYElementis$0.202.32%N/AN/AN/AOROCFAllkemN/AN/AN/AN/AN/AOXBDFOxford BioMedicaN/AN/AN/AN/AN/ALatest ELMTY, AOWDF, OROCF, OXBDF, and CGBD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025CGBDCarlyle Secured Lendingquarterly$0.4011.8%6/30/20256/30/20257/17/20254/29/2025ELMTYElementis$0.09351.81%5/2/20255/5/20256/16/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAOWDFAO WorldN/A0.760.50CGBDCarlyle Secured Lending1.033.553.55ELMTYElementis0.292.641.48OROCFAllkem0.082.522.23OXBDFOxford BioMedicaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAOWDFAO WorldN/ACGBDCarlyle Secured Lending24.51%ELMTYElementisN/AOROCFAllkemN/AOXBDFOxford BioMedicaN/AInsider OwnershipCompanyInsider OwnershipAOWDFAO WorldN/ACGBDCarlyle Secured Lending0.61%ELMTYElementisN/AOROCFAllkemN/AOXBDFOxford BioMedicaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAOWDFAO World4,442458.79 millionN/ANot OptionableCGBDCarlyle Secured LendingN/A50.96 million50.65 millionOptionableELMTYElementis1,200147.21 millionN/ANot OptionableOROCFAllkem1,350N/AN/ANot OptionableOXBDFOxford BioMedica891105.96 millionN/ANot OptionableELMTY, AOWDF, OROCF, OXBDF, and CGBD HeadlinesRecent News About These CompaniesOxford BioMedica (OTCMKTS:OXBDF) Trading Up 2.6% - Still a Buy?July 11 at 2:58 AM | marketbeat.comOxford BioMedica completes purchase of last 10% stake in US subsidiaryJune 23, 2025 | lse.co.ukOxford BioMedica (OTCMKTS:OXBDF) Trading Down 8.2% - What's Next?June 19, 2025 | marketbeat.comOxford BioMedica touts strong first-half momentum ahead of meetingJune 11, 2025 | lse.co.ukOxford Biomedica Full Year 2024 Earnings: EPS Beats ExpectationsMay 1, 2025 | finance.yahoo.comOxford BioMedica (OXBDF) Receives a Buy from RBC CapitalApril 15, 2025 | theglobeandmail.comWhen Will Oxford Biomedica plc (LON:OXB) Turn A Profit?April 10, 2025 | uk.finance.yahoo.comOxford Biomedica sees FY25 revenue GBP 160M-GBP 170MApril 9, 2025 | msn.comOxford Biomedica prepares statements on ‘going concern basis’April 9, 2025 | msn.comOxford Biomedica plc (OXBDF) Q4 2024 Earnings Call TranscriptApril 9, 2025 | seekingalpha.comOxford Biomedica annual loss narrows; hails "commercial momentum"April 9, 2025 | lse.co.ukOxford Biomedica to support Boehringer Ingelheim’s LENTICLAIR 1 trialFebruary 20, 2025 | markets.businessinsider.comOxford Biomedica appoints joint corporate broker, joint financial advisorFebruary 5, 2025 | markets.businessinsider.comOxford Biomedica Announces Total Voting Rights for 2024January 2, 2025 | markets.businessinsider.comOxford Biomedica Announces Total Voting RightsDecember 2, 2024 | markets.businessinsider.comOxford Biomedica Aligns Executive Incentives with GoalsNovember 23, 2024 | markets.businessinsider.comSanofi hands back gene therapies to Oxford BiomedicaNovember 15, 2024 | pharmaphorum.comPOxford Biomedica price target raised to 450 GBp from 305 GBp at JPMorganOctober 29, 2024 | markets.businessinsider.comOxford Biomedica Seeks Stock Market ExpansionOctober 22, 2024 | markets.businessinsider.comRBC Capital Sticks to Its Buy Rating for Oxford BioMedica (OXBDF)September 27, 2024 | markets.businessinsider.comOxford BioMedica: A Strong Buy on Undervaluation and Promising Growth ProspectsSeptember 24, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELMTY, AOWDF, OROCF, OXBDF, and CGBD Company DescriptionsAO World OTCMKTS:AOWDF$2.05 0.00 (0.00%) As of 12/15/2022AO World plc, together with its subsidiaries, engages in the online retailing of domestic appliances the United Kingdom and Germany. It retails fridge freezers, cookers and washing machines, and audiovisual equipment, as well as computing, mobile, gaming, and smart home technology products. The company also provides logistics and transport services. In addition, it engages in the investment activities; and waste electrical and electronic equipment (WEEE) recycling activities. The company sells its products through its websites, marketplaces, and third-party websites. AO World plc was founded in 2000 and is headquartered in Bolton, the United Kingdom.Carlyle Secured Lending NASDAQ:CGBD$14.17 +0.05 (+0.35%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Carlyle Secured Lending, Inc. is business development company specializing in first lien debt, senior secured loans, second lien senior secured loan unsecured debt, mezzanine debt and investments in equities. It specializes in directly investing. It specializes in middle market. It targets healthcare and pharmaceutical, aerospace and defense, high tech industries, business services, software, beverage food and tobacco, hotel gamming and leisure, banking finance insurance and in real estate sector. The fund seeks to invest across United States of America, Luxembourg, Cayman Islands, Cyprus, and United Kingdom. It invests in companies with EBITDA between $25 million and $100 million.Elementis OTCMKTS:ELMTY$8.61 0.00 (0.00%) As of 07/10/2025Elementis plc operates as a specialty chemical company in the United Kingdom, rest of Europe, North America, and internationally. It operates in two segments, Performance Specialties and Personal Care. The Performance Specialties segment engages in the production of rheological modifiers and additives for decorative and industrial coatings; and production and supply of talc for use in plastics, coatings, technical ceramics, and paper sectors. The Personal Care segment provides rheological modifiers and compounded products, including active ingredients for antiperspirants (AP) deodorants for personal care manufacturers. The company offers personal care products for antiperspirants, color cosmetics, and skin care applications; and performance specialties products for architectural coatings, adhesives, sealants and construction additives, and talc applications. Elementis plc was founded in 1844 and is headquartered in London, the United Kingdom.Allkem OTCMKTS:OROCF$6.80 +0.10 (+1.49%) As of 01/8/2024Allkem Limited engages in the production and sale of lithium and boron in Argentina. Its flagship project is the Olaroz Lithium Facility located in Jujuy province in northern Argentina. Allkem Limited was incorporated in 2005 and is headquartered in Brisbane, Australia.Oxford BioMedica OTCMKTS:OXBDF$4.77 0.00 (0.00%) As of 07/10/2025Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
